Clinical trials: Filovirus Infections
Hemorrhagic Fever, Ebola
Open Study of the Duration of Immunity After Vaccination With GamEvac
The purpose of this study is to evaluate the post-vaccination immune status at different time points in subjects immunized against Ebola Virus Disease; to select an optimal regimen of product administration; and, to assess safety…
- Trial name
- NCT02911428
- Testing
- blood sampling collection
- Where
- Russia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Ebola Virus Disease
Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC
A single arm, open-label, non-randomized, interventional phase 3 study to measure safety and effectiveness of a heterologous, two dose preventative vaccine (Ad26. ZEBOV, MVA-BN®-Filo) against Ebola Virus Disease.
- Trial name
- NCT04152486
- Testing
- Ad26.ZEBOV, MVA-BN-Filo vaccine
- Where
- Democratic Republic of the Congo
- Volunteers
- 20,426 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Healthy Adult Immune Responses to Vaccine
Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults
Background: Ebola is a virus that has infected and killed people mostly in West Africa. There is no treatment or prevention for it, but several drugs are being studied.
- Trial name
- NCT03478891
- Testing
- VRC-EBOMAB092-00-AB (MAb114)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy Adult Immune Responses to Vaccine
Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults
Background: Ebola virus causes an infection known as Ebola virus disease (EVD). This it is generally a severe disease which can also lead to death. The 2014 outbreak of EVD in West Africa is the largest ever.
- Trial name
- NCT02231866
- Testing
- VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP
- Where
- 3 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)
This is an open-label study evaluating the safety and immunogenicity of a booster dose of Ad26.ZEBOV administered to children who were previously vaccinated with Ad26.ZEBOV followed by MVA-BN-Filo 56 days later.
- Trial name
- NCT04711356
- Testing
- Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM injection
- Where
- Sierra Leone
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Ebola Virus Disease
EBOVAC-Salone Extension
The VAC52150EBL3005 (EBOVAC-Salone Extension) is a cohort study evaluating the long-term safety and immunogenicity of the candidate Ebola vaccines Ad26.ZEBOV and MVA-BN®-Filo in participants who were exposed to these vaccines in…
- Trial name
- NCT03820739
- Testing
- Follow-up, Blood sample collection
- Where
- 2 sites in Sierra Leone
- Volunteers
- 653 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Ebola Virus Disease
Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda
Screen participants attending 11 healthcare facilities in Mubende District for psychological distress using the locally validated Luganda or English version of the WHO- Self Report Questionnaire (SRQ-20).
- Trial name
- Ebola+D (NCT06093646)
- Testing
- Ebola+D intervention
- Where
- Uganda
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- MRC/UVRI and LSHTM Uganda Research Unit
Ebola Vaccine
Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers
This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be well tolerated and immunogenic.
- Trial name
- NCT02464670
- Testing
- INO-4201, INO-4202, INO-4212
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
Ebola Disease, Immunisation
A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)
This initial, proof of concept study will focus on identifying significant differences in response to the Ebolavirus Zaire vaccine (ChAd3-EBO-Z) when administered with placebo, MVA-BN(R)-Filo, or ChAd3-EBO-Z boosters after 8…
- Trial name
- NCT03583606
- Testing
- ChAd3-EBO-Z, MVA Multi-Filo Ebola Vaccine
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein
The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of two doses of the HPIV3/ΔHNF/EbovZ GP vaccine candidate when administered intranasally in healthy adults.
- Trial name
- NCT03462004
- Testing
- HPIV3/ΔHNF/EbovZ GP vaccine
- Where
- 2 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sudan Virus Disease
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health
A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health.
- Trial name
- NCT07565090
- Testing
- rVSVΔG-SUDV-GP
- Where
- 3 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
Ebola Hemorrhagic Fever
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers
The purpose of this study is to evaluate the safety and tolerability of healthy male and female subjects with intravenous (IV) infusions of AVI 7537 compared to matched placebo in and to evaluate the pharmacokinetics (PK).
- Trial name
- NCT01593072
- Testing
- AVI-7537, Normal Saline Solution (NSS)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Marburg Virus Disease
A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
- Trial name
- NCT06620003
- Testing
- cAd3-Marburg Vaccine
- Where
- 7 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Marburg Virus Disease
Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects
This is a Phase 1 randomized, single-blind, placebo-controlled, ascending dose study to evaluate the safety and immunogenicity of rVSV∆G-MARV-GP [Angola] (PHV01, Marburg Virus glycoprotein [MARV GP] Vaccine) in healthy adults.
- Trial name
- PHV01 (NCT06265012)
- Testing
- PHV01
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Public Health Vaccines LLC
Marburg Virus Disease
Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults
- Trial name
- NCT05817422
- Testing
- cAd3-Marburg vaccine
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Marburg Hemorrhagic Fever
Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
- Trial name
- NCT01353040
- Testing
- AVI-6003
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Ebola Virus Disease
Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III
Background: Ebola virus disease (EVD) is a viral fever that can cause internal bleeding. The death rate from EVD is very high. In a 2014 outbreak in West Africa, 28,000 were affected and 11,000 died.
- Trial name
- NCT05494801
- Where
- Liberia
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine
Interventional, single arm, open-label, non-randomized, phase IIIb study to accumulate additional data on safety and effectiveness of one dose of rVSVΔG-ZEBOV-GP against Ebola virus disease.
- Trial name
- NCT03161366
- Testing
- rVSVΔG-ZEBOV-GP
- Where
- 2 sites in Democratic Republic of the Congo, Uganda
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Epicentre
Ebola Virus Infection
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802
Phase 1, single-center, placebo-controlled, single-blind, first-in-human, single ascending dose (SAD) study followed by a multiple-dose cohort in healthy male and female subjects.
- Trial name
- NCT02041715
- Testing
- TKM-100802 for Injection
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Ebola Virus Disease
A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z
This is a clinical trial in which healthy volunteers will be administered experimental Ebola vaccines. The investigators will vaccinate four groups of volunteers.
- Trial name
- NCT02451891
- Testing
- MVA-EBO Z, ChAd3-EBO Z
- Where
- United Kingdom
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Oxford